Alvotech

ALVO

Market cap $1.15B

Alvotech is rated a speculative buy with a $4 price target, implying over 12% upside from current levels. ALVO posted double-digit revenue growth and positive GAAP profitability in FY 2025, but remains reliant on debt and minimal operating cash flow. 2026 catalysts include FDA approvals for key biosimilars and continued commercialization, with Selarsdi and AVT02 as major growth levers.

REYKJAVIK,  ICELAND (March 30, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”) has filed its Annual Report 2025 on Form 20-F for the financial year 2025 with the U.S. Securities and Exchange Commission (SEC), incorporating by reference parts of the Alvotech Annual Report 2025. The report is available on the SEC's website, www.sec.gov, as well as in the investor relations section of Alvotech's website at https://investors.alvotech.com/financials.

REYKJAVIK,  ICELAND (March 30, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”) has published its Annual Report for 2025. The report is available in the investor relations section of Alvotech's website at: https://investors.alvotech.com/financials and is attached to this announcement in PDF and iXBRL formats.

Alvotech (ALVO) Q4 2025 Earnings Call Transcript

A supplemental long ‑ form earnings release providing additional operational details and business update for Q4 2025 and the full year is available at: https://investors.alvotech.com/earnings-calendar The supplemental document is provided solely for reference and is not part of this SEC Form 6 ‑ K. The Form 6 ‑ K should not be read together with, or construed as referring to, the supplemental long ‑ form release.

Nine of the portfolio's 10 equity sectors made a positive impact on performance, with Health Care, Industrials, and Materials making the largest positive contributions. Palvella's shares appreciated significantly in 2025 as investors grew more confident in the company's pipeline following a grant from the FDA, patent wins, and a positive Phase II readout. Impinj is a long time holding in the portfolio with a very large total addressable market expansion opportunity, a strong patent portfolio, and an increasingly diversified customer base.

New York, New York--(Newsfile Corp. - February 11, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Alvotech (NASDAQ: ALVO) resulting from allegations that Alvotech may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Alvotech securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

REYKJAVIK,  ICELAND (February 11, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, has increased the Company´s share capital by an amount of one hundred and twenty-five thousand (USD 125,000) by issuing twelve million and five-hundred thousand (12,500,000) ordinary shares. The Company's subsidiary, Alvotech Manco ehf. (the “subsidiary”), has subscribed to all of the newly issued shares for a price of USD 5.2 per share. The shares held by the subsidiary are treated as treasury shares without voting rights or dividend entitlement.

NEW YORK, Feb. 09, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Alvotech (NASDAQ: ALVO) resulting from allegations that Alvotech may have issued materially misleading business information to the investing public.

NEW YORK, Feb. 9, 2026 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Alvotech (NASDAQ: ALVO) resulting from allegations that Alvotech may have issued materially misleading business information to the investing public. So What: If you purchased Alvotech securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.